Eloralintide

LY3841136

Last updated

Metabolic PeptideSelective Amylin Receptor AgonistResearchresearch-only

At a glance

Eloralintide (LY3841136) is an investigational peptide that mimics amylin, a hormone involved in satiety. In a 48-week randomized trial, adults receiving eloralintide lost an average of about 9% to 20% of their starting weight across treatment groups, compared with 0.4% on placebo. Nausea and fatigue were the most common adverse events. Phase 3 trials are studying the drug in adults with and without type 2 diabetes.

Available at Real Peptides (US) — 20% off auto-applied

Half-Life~14D
RouteSubQ
Dose Unitmg
Cycle24–48 weeks
Eloralintide before and after: illustrative male projection over 48 weeks, −12.1 lb fat, starting Fit & Toned with Above Average (+5 lb) body fat. Dose assumption: Dose not documented · total unavailable.
Before & afterExplore the projection →
Effectiveness Profile
Loading effectiveness chart
Fat Loss
7/10
Muscle Growth
0/10
Strength
0/10
Endurance
0/10
Recovery
0/10
Cognition
0/10

Overview

Eli Lilly is developing eloralintide for weight management. Early studies tested how long it stays in the body and whether participants tolerated repeated doses. A later study followed 263 adults for 48 weeks and measured the percentage change from each participant’s starting weight. That distinction matters when interpreting the results. A change on the scale can reflect changes in fat, lean tissue and water. Phase 1 study · Phase 2 study

How Eloralintide works

Which receptor does eloralintide activate?#

In cells expressing human receptors, eloralintide activated the amylin 1 receptor (AMY1) at a lower concentration than either of two related receptors. Its potency was about 11 times greater at AMY1 than at AMY3 and 12 times greater than at the calcitonin receptor. In rats with diet-induced obesity, food intake fell and most of the lost weight came from fat mass. The body-composition finding was specific to that animal model. Briere and colleagues

How long does it stay in the body?#

The phase 1 investigators describe slow absorption after subcutaneous administration and a half-life of roughly two weeks. Half-life is the time it takes the circulating concentration to fall by half. The study team measured drug exposure across the weekly interval. Bhattachar and colleagues

“The pharmacokinetic profile of eloralintide supports once-weekly dosing.” — Briere and colleagues

Protocol

The phase 2 trial assigned adults to placebo or to eloralintide under investigator supervision. The results below are group averages at week 48 from the published efficacy analysis. Each estimate applies to the study population under those conditions. Phase 2 study

Randomized study groupMean body-weight change
Placebo−0.4%
Fixed-dose groupsAbout −9% to −20%
Dose-escalation groupsAbout −16% to −20%

The trial enrolled adults with obesity, or overweight and a weight-related condition, and excluded type 2 diabetes. Its results cannot establish an effective dose for a lean athlete or a bodybuilding population.

Available at Real Peptides (US) — 20% off auto-applied

Cycle length & outcomes

Documented cycle

24–48 weeks

The 24–48 week range covers the two body-composition scans in the phase 2 trial. Investigators measured body fat with DXA (dual-energy X-ray absorptiometry). The illustration uses the lowest fixed-dose group as one example. These weeks describe the study observation window.

MilestoneWeekApproximate change from baseline
First DXA readout24~3.4 kg (7.5 lb) fat mass reduction in the 1 mg arm
Final DXA readout48~5.5 kg (12.1 lb) fat mass reduction in the 1 mg arm

The substudy included 135 participants across groups at week 24 and 122 at week 48. Lean mass also declined. DXA lean mass includes tissues besides skeletal muscle, so the illustration models fat loss only. Placebo participants also lost some fat. ObesityWeek 2025 symposium, slide 17

Both avatar settings use the same mixed-sex group estimate. The slider interpolates between the two scan results. The study did not measure weekly fat loss or establish an individual dosing cycle.

Loading outcome projection

Risks & mistakes

In phase 2, nausea affected 11% to 64% of participants across eloralintide groups and 14% on placebo. Fatigue ranged from 0% to 46% across active groups and occurred in 12% on placebo. Rates varied by assigned group, and several groups enrolled fewer than 30 people. The estimates are therefore imprecise. An earlier 12-week trial also recorded decreased appetite, headache, diarrhoea and vomiting. These trials provide limited information about rare or long-term harms. Phase 2 results · Phase 1 results

FAQ — Eloralintide

Where to buy Eloralintide

Real Peptides

Real Peptides

Our pick
Ships from USPeptide specialistVials, capsules & sprays

20% off — auto-applied at checkout

You'll also need

See the full where-to-buy guide for Eloralintide

Research & citations

3 studies cited on this page.

Conclusion

The 48-week trial provides evidence that eloralintide can reduce body weight in adults with obesity or overweight. Nausea and fatigue varied across treatment groups. The ongoing ENLIGHTEN trials study larger populations, including people with type 2 diabetes, and will help clarify the balance of benefits and harms. Phase 2 publication · ENLIGHTEN-2

Similar compounds

Disclosures

Affiliate links — we may earn a commission at no cost to you.